{"doi":"10.1002/cncr.34180","title":"Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","abstract":"BACKGROUND: Conditional survival estimates provide critical prognostic information for patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional survival outcomes were assessed in CheckMate 214 (ClinicalTrials.gov identifier NCT02231749) with a minimum follow-up of 5 years. METHODS: Patients with untreated aRCC were randomized to receive nivolumab (NIVO) (3 mg/kg) plus ipilimumab (IPI) (1 mg/kg) every 3 weeks for 4 cycles, then either NIVO monotherapy or sunitinib (SUN) (50 mg) daily (four 6-week cycles). Efficacy was assessed in intent-to-treat, International Metastatic Renal Cell Carcinoma Database Consortium intermediate-risk/poor-risk, and favorable-risk populations. Conditional survival outcomes (the probability of remaining alive, progression free, or in response 2 years beyond a specified landmark) were analyzed. RESULTS: The median follow-up was 67.7 months; overall survival (median, 55.7 vs 38.4 months; hazard ratio, 0.72), progression-free survival (median, 12.3 vs 12.3 months; hazard ratio, 0.86), and objective response (39.3% vs 32.4%) benefits were maintained with NIVO+IPI versus SUN, respectively, in intent-to-treat patients (N = 550 vs 546). Point estimates for 2-year conditional overall survival beyond the 3-year landmark were higher with NIVO+IPI versus SUN (intent-to-treat patients, 81% vs 72%; intermediate-risk/poor-risk patients, 79% vs 72%; favorable-risk patients, 85% vs 72%). Conditional progression-free survival and response point estimates were also higher beyond 3 years with NIVO+IPI. Point estimates for conditional overall survival were higher or remained steady at each subsequent year of survival with NIVO+IPI in patients stratified by tumor programmed death ligand 1 expression, grade ≥3 immune-mediated adverse event experience, body mass index, and age. CONCLUSIONS: Durable clinical benefits were observed with NIVO+IPI versus SUN at 5 years, the longest phase 3 follow-up for a first-line checkpoint inhibitor-based combination in patients with aRCC. Conditional estimates indicate that most patients who remained alive or in response with NIVO+IPI at 3 years remained so at 5 years.","journal":"Cancer","year":2022,"id":232106,"datarank":5.528127107259473,"base_score":5.583496308781699,"endowment":5.583496308781699,"self_citation_contribution":0.837524446317255,"citation_network_contribution":4.690602660942218,"self_endowment_contribution":0.837524446317255,"citer_contribution":4.690602660942218,"corpus_percentile":null,"corpus_rank":null,"citation_count":265,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9513,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02231749"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":95252,"name":"David F. McDermott","orcid":"0000-0002-2675-5095","position":1,"is_corresponding":false},{"id":91584,"name":"Bernard Escudier","orcid":"0000-0002-4626-0479","position":2,"is_corresponding":false},{"id":226675,"name":"Mauricio Burotto","orcid":"0000-0002-7150-4033","position":3,"is_corresponding":false},{"id":16405,"name":"Toni K. Choueiri","orcid":"0000-0002-9201-3217","position":4,"is_corresponding":false},{"id":232505,"name":"Hans J. Hammers","orcid":"0000-0002-6224-4559","position":5,"is_corresponding":false},{"id":645014,"name":"Philippe Barthélémy","orcid":"0009-0006-3868-186X","position":6,"is_corresponding":false},{"id":226676,"name":"Elizabeth R. Plimack","orcid":"0000-0002-7618-0744","position":7,"is_corresponding":false},{"id":226678,"name":"Camillo Porta","orcid":"0000-0003-2412-1563","position":8,"is_corresponding":false},{"id":226680,"name":"Saby George","orcid":"0000-0002-0444-5870","position":9,"is_corresponding":false},{"id":229488,"name":"Thomas Powles","orcid":null,"position":10,"is_corresponding":false},{"id":226679,"name":"Frede Donskov","orcid":"0000-0002-8449-863X","position":11,"is_corresponding":false},{"id":226682,"name":"Howard Gurney","orcid":"0000-0003-0217-5261","position":12,"is_corresponding":false},{"id":226681,"name":"Christian Kollmannsberger","orcid":"0000-0002-6329-761X","position":13,"is_corresponding":false},{"id":226683,"name":"Marc‐Oliver Grimm","orcid":"0000-0003-3084-8654","position":14,"is_corresponding":false},{"id":701719,"name":"Carlos H. Barrios","orcid":"0000-0001-6021-667X","position":15,"is_corresponding":false},{"id":226684,"name":"Yoshihiko Tomita","orcid":"0000-0002-7465-9591","position":16,"is_corresponding":false},{"id":105144,"name":"Daniel Castellano","orcid":"0000-0002-9106-0687","position":17,"is_corresponding":false},{"id":95442,"name":"Viktor Grünwald","orcid":"0000-0003-2083-7687","position":18,"is_corresponding":false},{"id":105189,"name":"Brian I. Rini","orcid":"0000-0002-2212-080X","position":19,"is_corresponding":false},{"id":226685,"name":"M. Brent McHenry","orcid":"0000-0001-9159-3304","position":20,"is_corresponding":false},{"id":645015,"name":"Chung‐Wei Lee","orcid":"0000-0002-3573-2506","position":21,"is_corresponding":false},{"id":842906,"name":"Jennifer L. McCarthy","orcid":null,"position":22,"is_corresponding":false},{"id":842907,"name":"Flavia Ejzykowicz","orcid":null,"position":23,"is_corresponding":false},{"id":226674,"name":"Nizar M. Tannir","orcid":"0000-0001-5559-8060","position":24,"is_corresponding":false},{"id":226686,"name":"Robert J. Motzer","orcid":"0000-0001-6925-2327","position":0,"is_corresponding":true}],"reference_count":16,"raw_metadata":null,"created_at":"2026-07-19T00:21:12.348693Z","pmid":"35383908","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}